A Meta-analysis of CXCL12 Expression for Cancer Prognosis

Overview

Journal Br J Cancer

Specialty Oncology

Date 2017 May 24

PMID 28535157

Citations 61

Authors

Harsh Samarendra

Keaton Jones

Tatjana Petrinic

Michael A Silva

Srikanth Reddy

Zahir Soonawalla

Alex Gordon-Weeks

Affiliations

Soon will be listed here.

Abstract

Background: CXCL12 (SDF1) is reported to promote cancer progression in several preclinical models and this is corroborated by the analysis of human tissue specimens. However, the relationship between CXCL12 expression and cancer survival has not been systematically assessed.

Methods: We conducted a systematic review and meta-analysis of studies that evaluated the association between CXCL12 expression and cancer survival.

Results: Thirty-eight studies inclusive of 5807 patients were included in the analysis of overall, recurrence-free or cancer-specific survival, the majority of which were retrospective. The pooled hazard ratios (HRs) for overall and recurrence-free survival in patients with high CXCL12 expression were 1.39 (95% CI: 1.17-1.65, P=0.0002) and 1.12 (95% CI: 0.82-1.53, P=0.48) respectively, but with significant heterogeneity between studies. On subgroup analysis by cancer type, high CXCL12 expression was associated with reduced overall survival in patients with oesophagogastric (HR 2.08; 95% CI: 1.31-3.33, P=0.002), pancreatic (HR 1.54; 95% CI: 1.21-1.97, P=0.0005) and lung cancer (HR 1.37; 95% CI: 1.08-1.75, P=0.01), whereas in breast cancer patients high CXCL12 expression conferred an overall survival advantage (HR 0.5; 95% CI: 0.38-0.66, P<0.00001).

Conclusions: Determination of CXCL12 expression has the potential to be of use as a cancer biomarker and adds prognostic information in various cancer types. Prospective or prospective-retrospective analyses of CXCL12 expression in clearly defined cancer cohorts are now required to advance our understanding of the relationship between CXCL12 expression and cancer outcome.

Citing Articles

Establishment and application of a zebrafish model of Werner syndrome identifies sapanisertib as a potential antiaging drug.

Ma J, Chen Y, Song J, Ruan Q, Li L, Luo L Proc Natl Acad Sci U S A. 2025; 122(5):e2413719122.

PMID: 39883840 PMC: 11804616. DOI: 10.1073/pnas.2413719122.

The role of the CXCL12/CXCR4 axis in the immunotherapy of non-small cell lung cancer.

Rogado J, Pozo F, Troule K, Pacheco M, Adrados M, Sanchez-Torres J Clin Transl Oncol. 2024; .

PMID: 39708256 DOI: 10.1007/s12094-024-03828-3.

The Effect of C-X-C Motif Chemokine Ligand 12 in Colorectal Cancer Associated with Chemoresistance and Radioresistance as Well as Stemness.

Dong W, Lin W, Li C Iran J Public Health. 2024; 53(9):2079-2089.

PMID: 39429654 PMC: 11490330. DOI: 10.18502/ijph.v53i9.16461.

CXCL12 chemokine dimer signaling modulates acute myelogenous leukemia cell migration through altered receptor internalization.

Drouillard D, Halyko M, Cinquegrani E, McAllister D, Peterson F, Marchese A bioRxiv. 2024; .

PMID: 39253415 PMC: 11383031. DOI: 10.1101/2024.08.26.609725.

Unveiling clinical significance and tumor immune landscape of CXCL12 in bladder cancer: Insights from multiple omics analysis.

Tuo Z, Feng D, Jiang Z, Bi L, Yang C, Wang Q Chin J Cancer Res. 2024; 35(6):686-701.

PMID: 38204439 PMC: 10774138. DOI: 10.21147/j.issn.1000-9604.2023.06.12.

References

Wang Q, Diao X, Sun J, Chen Z . Stromal cell-derived factor-1 and vascular endothelial growth factor as biomarkers for lymph node metastasis and poor cancer-specific survival in prostate cancer patients after radical prostatectomy. Urol Oncol. 2011; 31(3):312-7. DOI: 10.1016/j.urolonc.2011.01.006. View

Kadota K, Nitadori J, Ujiie H, Buitrago D, Woo K, Sima C . Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma: Tumor-Infiltrating CD10+ Neutrophil/CD20+ Lymphocyte Ratio as an Independent Prognostic Factor. J Thorac Oncol. 2015; 10(9):1301-1310. PMC: 4545576. DOI: 10.1097/JTO.0000000000000617. View

Schrevel M, Karim R, ter Haar N, van der Burg S, Trimbos J, Fleuren G . CXCR7 expression is associated with disease-free and disease-specific survival in cervical cancer patients. Br J Cancer. 2012; 106(9):1520-5. PMC: 3341866. DOI: 10.1038/bjc.2012.110. View

Wang X, Zhang H, He H, Shen Z, Tang Z, Xu J . Prognostic value of stromal cell-derived factor 1 expression in patients with gastric cancer after surgical resection. Cancer Sci. 2014; 105(11):1447-56. PMC: 4462371. DOI: 10.1111/cas.12531. View

Chau C, Rixe O, Mcleod H, Figg W . Validation of analytic methods for biomarkers used in drug development. Clin Cancer Res. 2008; 14(19):5967-76. PMC: 2744124. DOI: 10.1158/1078-0432.CCR-07-4535. View

Goto M, Yoshida T, Yamamoto Y, Furukita Y, Inoue S, Fujiwara S . CXCR4 Expression is Associated with Poor Prognosis in Patients with Esophageal Squamous Cell Carcinoma. Ann Surg Oncol. 2015; 24(3):832-840. DOI: 10.1245/s10434-015-4974-5. View

Fu Z, Wang F, Cai J . Gene expression changes in residual advanced cervical cancer after radiotherapy: indicators of poor prognosis and radioresistance?. Med Sci Monit. 2015; 21:1276-87. PMC: 4432617. DOI: 10.12659/MSM.893689. View

Grivennikov S, Greten F, Karin M . Immunity, inflammation, and cancer. Cell. 2010; 140(6):883-99. PMC: 2866629. DOI: 10.1016/j.cell.2010.01.025. View

Kobayashi T, Tsuda H, Moriya T, Yamasaki T, Kikuchi R, Ueda S . Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis. Breast Cancer Res Treat. 2009; 123(3):733-45. DOI: 10.1007/s10549-009-0672-y. View

10.

Ludwig J, Weinstein J . Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005; 5(11):845-56. DOI: 10.1038/nrc1739. View

11.

Wendt M, Cooper A, Dwinell M . Epigenetic silencing of CXCL12 increases the metastatic potential of mammary carcinoma cells. Oncogene. 2007; 27(10):1461-71. DOI: 10.1038/sj.onc.1210751. View

12.

Sterlacci W, Saker S, Huber B, Fiegl M, Tzankov A . Expression of the CXCR4 ligand SDF-1/CXCL12 is prognostically important for adenocarcinoma and large cell carcinoma of the lung. Virchows Arch. 2016; 468(4):463-71. DOI: 10.1007/s00428-015-1900-y. View

13.

Martinetti A, Miceli R, Sottotetti E, Di Bartolomeo M, De Braud F, Gevorgyan A . Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens. Cancers (Basel). 2014; 6(3):1753-68. PMC: 4190566. DOI: 10.3390/cancers6031753. View

14.

Yan M, Jene N, Byrne D, Millar E, OToole S, McNeil C . Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Res. 2011; 13(2):R47. PMC: 3219210. DOI: 10.1186/bcr2869. View

15.

de Visser K, Eichten A, Coussens L . Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006; 6(1):24-37. DOI: 10.1038/nrc1782. View

16.

Wani N, Nasser M, Ahirwar D, Zhao H, Miao Z, Shilo K . C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment. Breast Cancer Res. 2014; 16(3):R54. PMC: 4076630. DOI: 10.1186/bcr3665. View

17.

Razis E, Kalogeras K, Kotoula V, Eleftheraki A, Nikitas N, Kronenwett R . Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression. Clin Breast Cancer. 2012; 12(3):183-93. DOI: 10.1016/j.clbc.2012.03.006. View

18.

Chow M, Luster A . Chemokines in cancer. Cancer Immunol Res. 2014; 2(12):1125-31. PMC: 4258879. DOI: 10.1158/2326-6066.CIR-14-0160. View

19.

Tsuboi K, Kodera Y, Nakanishi H, Ito S, Mochizuki Y, Nakayama G . Expression of CXCL12 and CXCR4 in pT3-stage gastric cancer does not correlate with peritoneal metastasis. Oncol Rep. 2008; 20(5):1117-23. View

20.

de Cuba E, de Hingh I, Sluiter N, Kwakman R, Coupe V, Belien J . Angiogenesis-Related Markers and Prognosis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer. Ann Surg Oncol. 2016; 23(5):1601-8. PMC: 4819744. DOI: 10.1245/s10434-015-5023-0. View